OBJECTIVE: To examine the association between macrophage migration inhibitory factor (MIF) promoter polymorphisms and granulomatosis with polyangiitis (GPA) in human subjects, and to assess the role of MIF in a murine model of granulomatous vasculitis. METHODS: The human study involved 1,077 patients with GPA and healthy controls whose serum was genotyped by capillary electrophoresis for the MIF -794 CATT5-8 promoter microsatellite (rs5844572). MIF promoter, CATT-length-dependent gene expression in response to β-glucan was assessed by gene reporter assays. In mouse studies, granulomatous disease was induced by injection of Candida albicans β-glucan into wild-type (WT) or Mif-knockout (Mif-KO) C57BL/6 mice and C57BL/6 mice transgenically overexpressing Mif in lung epithelium (Mif lung-Tg2.1). Mice were treated with a neutralizing anti-MIF antibody and analyzed for the density of pulmonary granulomas, expression of inflammatory chemokines, and frequency of mortality. RESULTS: The percentage of human subjects carrying >5 CATT repeats in each MIF allele (high genotypic MIF expressers) was 60.2% among patients with GPA and 53.9% among healthy controls (adjusted P = 0.049). In response to granulomatous stimulation, human MIF gene expression increased proportionally with CATT length. Mif lung-Tg2.1 mice exhibited more pulmonary granulomas than WT mice, which in turn showed more granulomas than Mif-KO mice. A significantly higher percentage of Mif lung-Tg2.1 mice, compared to Mif-KO or WT mice, died when injected with Candida albicans β-glucan, and treatment of these mice with an anti-MIF monoclonal antibody protected against a lethal outcome. Levels of MIF-dependent neutrophil/macrophage chemokines were elevated in the bronchoalveolar lavage fluid or plasma of Mif lung-Tg2.1 mice. CONCLUSION: Patients with GPA have an increased frequency of high MIF expression CATT alleles. Higher Mif expression increases the incidence of mortality and pulmonary granulomas in Mif lung-Tg2.1 mice, while anti-MIF treatment protects these mice against death. Blockade of MIF in high genotypic MIF expressers may therefore offer a selective pharmacologic therapy for GPA.
OBJECTIVE: To examine the association between macrophage migration inhibitory factor (MIF) promoter polymorphisms and granulomatosis with polyangiitis (GPA) in human subjects, and to assess the role of MIF in a murine model of granulomatous vasculitis. METHODS: The human study involved 1,077 patients with GPA and healthy controls whose serum was genotyped by capillary electrophoresis for the MIF -794 CATT5-8 promoter microsatellite (rs5844572). MIF promoter, CATT-length-dependent gene expression in response to β-glucan was assessed by gene reporter assays. In mouse studies, granulomatous disease was induced by injection of Candida albicans β-glucan into wild-type (WT) or Mif-knockout (Mif-KO) C57BL/6 mice and C57BL/6 mice transgenically overexpressing Mif in lung epithelium (Mif lung-Tg2.1). Mice were treated with a neutralizing anti-MIF antibody and analyzed for the density of pulmonary granulomas, expression of inflammatory chemokines, and frequency of mortality. RESULTS: The percentage of human subjects carrying >5 CATT repeats in each MIF allele (high genotypic MIF expressers) was 60.2% among patients with GPA and 53.9% among healthy controls (adjusted P = 0.049). In response to granulomatous stimulation, humanMIF gene expression increased proportionally with CATT length. Mif lung-Tg2.1 mice exhibited more pulmonary granulomas than WT mice, which in turn showed more granulomas than Mif-KO mice. A significantly higher percentage of Mif lung-Tg2.1 mice, compared to Mif-KO or WT mice, died when injected with Candida albicans β-glucan, and treatment of these mice with an anti-MIF monoclonal antibody protected against a lethal outcome. Levels of MIF-dependent neutrophil/macrophage chemokines were elevated in the bronchoalveolar lavage fluid or plasma of Mif lung-Tg2.1 mice. CONCLUSION:Patients with GPA have an increased frequency of high MIF expression CATT alleles. Higher Mif expression increases the incidence of mortality and pulmonary granulomas in Mif lung-Tg2.1 mice, while anti-MIF treatment protects these mice against death. Blockade of MIF in high genotypic MIF expressers may therefore offer a selective pharmacologic therapy for GPA.
Authors: Shannon D McClintock; Adam G Barron; Eric W Olle; Michael P Deogracias; Roscoe L Warner; Mark R Opp; Kent J Johnson Journal: Exp Mol Pathol Date: 2007-01-12 Impact factor: 3.362
Authors: Y P de Jong; A C Abadia-Molina; A R Satoskar; K Clarke; S T Rietdijk; W A Faubion; E Mizoguchi; C N Metz; M Alsahli; T ten Hove; A C Keates; J B Lubetsky; R J Farrell; P Michetti; S J van Deventer; E Lolis; J R David; A K Bhan; C Terhorst; M A Sahli Journal: Nat Immunol Date: 2001-11 Impact factor: 25.606
Authors: G Fingerle-Rowson; O Petrenko; C N Metz; T G Forsthuber; R Mitchell; R Huss; U Moll; W Müller; R Bucala Journal: Proc Natl Acad Sci U S A Date: 2003-07-23 Impact factor: 11.205
Authors: M A Llamas-Covarrubias; Y Valle; R Bucala; R E Navarro-Hernández; C A Palafox-Sánchez; J R Padilla-Gutiérrez; I Parra-Rojas; A G Bernard-Medina; Z Reyes-Castillo; J F Muñoz-Valle Journal: Cytokine Date: 2013-02-09 Impact factor: 3.861
Authors: Sachin Yende; Derek C Angus; Lan Kong; John A Kellum; Lisa Weissfeld; Robert Ferrell; David Finegold; Melinda Carter; Lin Leng; Zhi-Yong Peng; Richard Bucala Journal: FASEB J Date: 2009-04-03 Impact factor: 5.191
Authors: Candice A Smith; Daniel J Tyrell; Upasana A Kulkarni; Sherri Wood; Lin Leng; Rachel L Zemans; Richard Bucala; Daniel R Goldstein Journal: JCI Insight Date: 2019-07-11
Authors: Guillermo Santoscoy-Ascencio; Christian Johana Baños-Hernández; José Eduardo Navarro-Zarza; Jorge Hernández-Bello; Richard Bucala; Andres López-Quintero; Emmanuel Valdés-Alvarado; Isela Parra-Rojas; Berenice Illades-Aguiar; José Francisco Muñoz-Valle Journal: Mol Genet Genomic Med Date: 2019-11-07 Impact factor: 2.183